INDICATION & USAGE
IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.
Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.
Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).
Please see full Prescribing Information.
Learn about the devastating consequences of JE through first-person accounts, as real patients and families affected by JE share their stories.
JE Educational Resources
This section contains practical information about Japanese encephalitis (JE) for healthcare professionals, including videos, on-demand learning modules, case studies, a JE risk map, and other resources.
Japanese Encephalitis: Patient Stories
Hear from real patients and their families about the devastating consequences of JE.
CHELSEA’S STORY
A young woman performing volunteer work in Thailand becomes infected with JE virus. Her path to recovery is long and arduous.
JOHN’S STORY
A single mosquito bite alters the lives of a family. Parents Kathy and Ed share the life-changing consequences JE had on their son John, now left with quadriplegia.
SOPHIE’S STORY
A trip to China ends abruptly as a young scientist is hospitalized in a coma and remains paralyzed. Her father Mike narrates how the family cares for their daughter’s profound medical needs.
Raise Your JE IQ: What You Need to Know to Protect Travelers to Asia
Travelers to any of 24 endemic countries in Asia may be at risk for Japanese encephalitis (JE). Get expert, practical advice on preventing JE from Dr. Davidson H. Hamer.
JE Vaccine Considerations and Counseling
This short video contains knowledge you can apply to your practice, including suggestions for effective HCP–traveler conversations to assess JE risk and tips for protecting travelers and overcoming vaccine hesitancy.
JE Learning Modules and Quiz
To learn more about JE, please view these on-demand educational videos and take the JE IQ Quiz to test your knowledge.
What is JE?
JE Virus
JE Epidemiology
JE Risk
JE Disease Outcomes
Protection from JE
JE Vaccine
The 3 O’s of JE Vaccination
JE IQ Quiz
Click to View Resources
JE Risk Map
Scientific Article: ‘More than devastating’—patient experiences and neurological sequelae of Japanese encephalitis
Case Study: Disease Recovery in a Traveler to China
Indication & Usage
IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.
Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.
Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO), or +1-301-556-4500.
Please see full Prescribing Information.
Valneva USA, Inc.
4550 Montgomery Ave.,
Suite 460
Bethesda, MD 20814
USA
Customer Service
+1-833-403-8778
Medical Information
+1 844 349 4276
(8443-IXIARO)
or +1-301-556-4500
This website is intended for US-based healthcare professionals.
US-IXI-2200027 | Copyright © 2022 Valneva USA, Inc. All Rights Reserved.
